Scinai Immunotherapeutics LT
13F holders, Q2 2025 (June 30)6holders +2
2new positions
0sold out
1famous investor
$2.28avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were Yorkville Advisors Global, LP ($96K), UBS Group AG ($27K) and Citadel Advisors ($27K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Scinai Immunotherapeutics LT
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $49K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 23,515 shares bought and 2,876 shares sold, net +20,639 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Yorkville Advisors Global, LP | 0.03% | — | 42,000 | $96K |
| UBS Group AG | 0.00% | Reduce -19.3% | 12,056 | $27K |
| Citadel Advisors | 0.00% | New | 11,599 | $27K |
| Bank of Montreal | 0.00% | New | 10,000 | $23K |
| Rhumbline Advisers | 0.00% | Add +122.3% | 3,483 | $8K |
| Morgan Stanley | 0.00% | No change | 255 | $581 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.